34622-39-4|(S)-2-Piperidinone-6-carboxylic acid| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 34622-39-4 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 34622-39-4 ]

CAS No. :	34622-39-4
Formula :	C₆H₉NO₃
M.W :	143.14
SMILES Code :	OC([C@H]1NC(CCC1)=O)=O
MDL No. :	MFCD03839863
InChI Key :	FZXCPFJMYOQZCA-BYPYZUCNSA-N
Pubchem ID :	11126383

Safety of [ 34622-39-4 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 34622-39-4 ] Show Less

Physicochemical Properties

Num. heavy atoms	10
Num. arom. heavy atoms	0
Fraction Csp3	0.67
Num. rotatable bonds	1
Num. H-bond acceptors	3.0
Num. H-bond donors	2.0
Molar Refractivity	37.53
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	66.4 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.66
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	-0.41
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-0.64
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-0.55
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.15
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	-0.16

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-0.4
Solubility	56.6 mg/ml ; 0.395 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-0.52
Solubility	43.2 mg/ml ; 0.302 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.33
Solubility	67.4 mg/ml ; 0.471 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-7.46 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.56

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.71

Application In Synthesis of [ 34622-39-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 34622-39-4 ]

[ 34622-39-4 ] Synthesis Path-Downstream 1~35

1
[ 1117-96-0 ]
[ 34622-39-4 ]
[ 128726-44-3 ]

References: [1]Synthetic Communications,1989,vol. 19,p. 3485 - 3496.

2
[ 15761-39-4 ]
[ 34622-39-4 ]
[ 25024-53-7 ]
[ 57818-01-6 ]

References: [1]Journal of Medicinal Chemistry,1981,vol. 24,p. 692 - 698.

3
[ 1118-90-7 ]
[ 34622-39-4 ]

Yield	Reaction Conditions	Operation in experiment
45%	With water; acetic acid; for 3h;Inert atmosphere; Reflux;	(a) (S)-6-Oxo-piperidine-2-carboxylic acid A mixture of (S)-2-amino-hexanedioic acid (50 g, 310.25 mmol), acetic acid (100 mL), and water (400 mL) water was refluxed for 3 h. The unchanged starting amino acid was filtered off (24 g) and the filtrate evaporated, dissolved in hot water (50 mL) and then cooled. A crystalline precipitate formed which was filtered to provide the title intermediate (20 g, 45percent yield).
	In ethanol;	Step A. (S)-6-Oxopiperidine-2-carboxylic acid A solution of (S)-2-aminohexanedioic acid (470 mg, 2.9 mmol) in 20percent AcOH (5 mL) was stirred at 110° C. overnight. The solvent was removed in vacuo and the residue was dissolved in EtOH (10 mL). The unreacted amino acid was precipitated and filtered off. The filtrate was concentrated to give the crude desired product which was used directly in the next step. MS: 142.1 (M-1)-.
	With acetic acid; at 110℃;	Example 6. Preparation of (S)-N-((S)-l-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl) - amino)-2-oxoethyl)-N-(3-fluorophenyl)-6-oxo-l-(pyrimidin-2-yl)piperidine-2-carboxamide Compounds 19 and 20 were prepared according to the following scheme, using the following protocol. Step A. (S)-6-Oxopiperidine-2-carboxylic acid. A solution of (S)-2-aminohexanedioic acid (470 mg, 2.9 mmol) in 20percent AcOH (5 niL) was stirred at 1 10 °C overnight. The solvent was removed in vacuo and the residue was dissolved in EtOH (10 mL). The unreacted amino acid was precipitated and filtered off. The filtrate was concentrated to give the crude desired product which was used directly in the next step. MS: 142.1 (M-l)\

	With acetic acid; at 110℃;	A solution of (S)-2-aminohexanedioic acid (470mg, 2.9 mmol) in 20percent AcOH (5 mL) was stirred at 110 °C overnight. The solvent was removed in vacuo and the residue was dissolved in EtOH (lOmL). The unreacted amino acid was precipitated and filtered off. The filtrate was concentrated to give the crude desired product which was used directly in the next step. MS: 142.1 (M-1).
	With acetic acid; at 110℃;	Step A. (S)-6-Oxopiperidine-2-carboxylic acid. A solution of (S)-2-aminohexanedioic acid (470 mg, 2.9 mmol) in 20percent AcOH (5 mL) was stirred at 1 10 °C overnight. The solvent was removed in vacuo and the residue was dissolved in EtOH ( 10 mL). The unreacted amino acid was precipitated and filtered off. The filtrate was concentrated to give the crude desired product which was used directly in the next step. MS: 142. 1 (M- l )'.

References: [1]Chemical and Pharmaceutical Bulletin,1999,vol. 47,p. 1525 - 1531.
[2]Journal of the American Chemical Society,1982,vol. 104,p. 4446 - 4450.
[3]Journal of Medicinal Chemistry,1986,vol. 29,p. 1654 - 1658.
[4]Chemical Communications,2010,vol. 46,p. 1413 - 1415.
[5]Patent: US2013/287731,2013,A1 .Location in patent: Paragraph 0295; 0296.
[6]Patent: US2013/190249,2013,A1 .Location in patent: Page/Page column.
[7]Patent: WO2013/107291,2013,A1 .Location in patent: Page/Page column 92; 93.
[8]Patent: WO2015/10626,2015,A1 .Location in patent: Page/Page column 93.
[9]Patent: WO2015/10297,2015,A1 .Location in patent: Page/Page column 93.

4
[ 771-61-9 ]
[ 34622-39-4 ]
[ 78664-72-9 ]

References: [1]Journal of Medicinal Chemistry,1986,vol. 29,p. 1654 - 1658.

5
[ 34622-39-4 ]
[ 77897-78-0 ]
[ 77897-79-1 ]

References: [1]Journal of Medicinal Chemistry,1981,vol. 24,p. 692 - 698.

6
[ 34622-39-4 ]
[ 128726-47-6 ]

References: [1]Synthetic Communications,1989,vol. 19,p. 3485 - 3496.
[2]Synthetic Communications,1989,vol. 19,p. 3485 - 3496.
[3]Patent: US2013/287731,2013,A1 .

7
<*>Ac-DL-Aad-OH [ No CAS ]
[ 34622-39-4 ]

References: [1]Journal of Medicinal Chemistry,1981,vol. 24,p. 692 - 698.

8
(S)-4-Guanidino-2-[((S)-1-{(S)-5-guanidino-2-[(S)-2-((S)-4-methyl-2-{(S)-2-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-3-phenyl-propionylamino}-pentanoylamino)-3-phenyl-propionylamino]-pentanoyl}-pyrrolidine-2-carbonyl)-amino]-butyric acid [ No CAS ]
[ 1118-90-7 ]
[ 34622-39-4 ]
(S)-2-[(S)-1-((S)-2-{(S)-2-[(S)-2-((S)-2-Amino-3-phenyl-propionylamino)-4-methyl-pentanoylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-4-guanidino-butyric acid [ No CAS ]
(S)-5-Amino-5-{(S)-1-[(S)-1-((S)-1-{(S)-1-[(S)-2-((S)-1-carboxy-3-guanidino-propylcarbamoyl)-pyrrolidine-1-carbonyl]-4-guanidino-butylcarbamoyl}-2-phenyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-2-phenyl-ethylcarbamoyl}-pentanoic acid [ No CAS ]

References: [1]Chemical and Pharmaceutical Bulletin,1995,vol. 43,p. 2068 - 2074.

9
[ 34622-39-4 ]
[ 908093-98-1 ]
[ 216315-22-9 ]